Tema Oncology Competition
| CANC Etf | 36.58 1.01 2.84% |
Tema Oncology vs Invesco SP Correlation
Poor diversification
The correlation between Tema Oncology ETF and CSD is 0.75 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Tema Oncology ETF and CSD in the same portfolio, assuming nothing else is changed.
Moving together with Tema Etf
Tema Oncology Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Tema Oncology and its competitors represents the degree of relationship between the price movements of corresponding etfs. A correlation of about +1.0 implies that the price of Tema and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Tema Oncology ETF does not affect the price movement of the other competitor.
Tema Oncology Constituents Risk-Adjusted Indicators
There is a big difference between Tema Etf performing well and Tema Oncology ETF doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Tema Oncology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| MINV | 0.92 | (0.01) | (0.06) | 0.02 | 1.12 | 2.25 | 5.50 | |||
| OVLH | 0.37 | (0.03) | 0.00 | 1.37 | 0.00 | 0.73 | 2.67 | |||
| SPBC | 0.67 | 0.00 | 0.00 | 0.00 | 0.00 | 1.20 | 4.89 | |||
| KARS | 1.06 | (0.02) | (0.03) | 0.05 | 1.28 | 2.42 | 6.31 | |||
| PSMD | 0.20 | 0.01 | (0.18) | (0.39) | 0.28 | 0.55 | 1.86 | |||
| BATT | 1.49 | 0.10 | 0.05 | 0.16 | 2.24 | 3.11 | 10.06 | |||
| MAVF | 0.68 | 0.05 | 0.05 | 0.13 | 0.66 | 1.43 | 3.52 | |||
| CVMC | 0.64 | 0.07 | (0.01) | 1.76 | 0.71 | 1.57 | 3.87 | |||
| ONLN | 1.11 | (0.19) | 0.00 | (0.10) | 0.00 | 1.89 | 5.75 | |||
| CSD | 1.29 | 0.12 | 0.10 | 0.15 | 1.41 | 2.84 | 6.73 |
Tema Oncology Competitive Analysis
The better you understand Tema Oncology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Tema Oncology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Tema Oncology's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Tema Oncology Competition Performance Charts
Five steps to successful analysis of Tema Oncology Competition
Tema Oncology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Tema Oncology ETF in relation to its competition. Tema Oncology's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Tema Oncology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Tema Oncology's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Tema Oncology ETF, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Tema Oncology position
In addition to having Tema Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investor Favorites Thematic Idea Now
Investor Favorites
Macroaxis most traded equities with largest long positions over the last 2 years. The Investor Favorites theme has 21 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investor Favorites Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Tema Oncology Correlation with its peers. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Understanding Tema Oncology ETF requires distinguishing between market price and book value, where the latter reflects Tema's accounting equity. The concept of intrinsic value - what Tema Oncology's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Tema Oncology's price substantially above or below its fundamental value.
It's important to distinguish between Tema Oncology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Tema Oncology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Tema Oncology's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.